Clinical and laboratory findings in patients with fiban-induced thrombocytopenia
| Drug . | Tirofiban . | Eptifibatide . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient sample . | T1 . | T2 . | T3 . | T4 . | E1 . | E2 . | E3 . | E4 . | E5 . |
| Sex/age, y | M/78 | M/65 | M/64 | F/78 | M/73 | F/81 | F/79 | F/59 | M/65 |
| Prior drug exposure | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Pretreatment platelet level* | 212 | 200 | 192 | 200 | 195 | 220 | 225 | 196 | 90 |
| Platelet nadir* | 1 | 19 | 5 | 2 | 25 | 9 | 2 | 5 | 2 |
| Days to reach 100* | 4 | 3 | Died | > 5 | 4 | 3 | 4 | > 5 | > 5 |
| Platelet transfusion | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes |
| Antibody Ig class | IgG | IgG | IgG | IgG/M (w) | IgG | IgG | IgG | IgG/M (w) | IgG |
| Antibody titer | 1:1 280 | 1:80 | 1:1 000 | 1:10 000 | 1:20 000 | 1:5 000 | 1:1 280 | 1:5 000 | 1:320 |
| Drug . | Tirofiban . | Eptifibatide . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient sample . | T1 . | T2 . | T3 . | T4 . | E1 . | E2 . | E3 . | E4 . | E5 . |
| Sex/age, y | M/78 | M/65 | M/64 | F/78 | M/73 | F/81 | F/79 | F/59 | M/65 |
| Prior drug exposure | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Pretreatment platelet level* | 212 | 200 | 192 | 200 | 195 | 220 | 225 | 196 | 90 |
| Platelet nadir* | 1 | 19 | 5 | 2 | 25 | 9 | 2 | 5 | 2 |
| Days to reach 100* | 4 | 3 | Died | > 5 | 4 | 3 | 4 | > 5 | > 5 |
| Platelet transfusion | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes |
| Antibody Ig class | IgG | IgG | IgG | IgG/M (w) | IgG | IgG | IgG | IgG/M (w) | IgG |
| Antibody titer | 1:1 280 | 1:80 | 1:1 000 | 1:10 000 | 1:20 000 | 1:5 000 | 1:1 280 | 1:5 000 | 1:320 |
Platelet level in thousands per microliter. w indicates weak.